Lorlatinib in ALK+ NSCLC: Robust Phase II Efficacy Seen [News in Brief]

Investigational drug is well tolerated, induces confirmed responses across five cohorts.

from Cancer via ola Kala on Inoreader http://ift.tt/2zhgnBs
via IFTTT